AI
CMPX icon

Atom Investors’s Compass Therapeutics CMPX Stock Holding History

Atom Investors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-344,933
Closed -$1.82M – 859
2026
Q1 		$1.82M Buy
344,933
+267,652
+346% +$1.54M 0.13% 258
2025
Q4 		$415K Sell
77,281
-29,393
-28% -$136K 0.03% 404
2025
Q3 		$373K Buy
+106,674
New +$337K 0.03% 408

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Atom Investors's CMPX Position: Q2 2026 in Review

Atom Investors sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 344,933 shares — an estimated $1.82M sold.

Atom Investors first reported a position in CMPX in Q3 2025 and held it in 3 quarters. The position peaked at $1.82M in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Atom Investors reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Atom Investors sold 344,933 Compass Therapeutics shares in Q2 2026, an estimated $1.82M.
  • Atom Investors first reported a position in Compass Therapeutics in Q3 2025 and held it in 3 quarters.
  • Atom Investors's Compass Therapeutics position peaked at $1.82M in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.